Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.

The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

Minoxidil can prevent hair follicle miniaturization, not just stimulate hair growth. Finasteride and dutasteride don't work for everyone, suggesting DHT may not be the sole cause of hair loss; hair loss could be due to multiple factors, including autoimmune conditions.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The post discusses a hair loss treatment regimen using saw palmetto, pumpkin seed oil extract, EGCG (green tea) extract, grape seed oil extract, rosemary oil extract, and Zix. The user plans to use these DHT-blockers and 5AR inhibitors for six months and report the results.

The conversation is about which blood markers to test before starting a 5-AR inhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.

Controlling insulin levels through intermittent fasting and a low glycemic diet may improve hair quality by reducing androgens. It's important to maintain proper nutrition, including electrolytes and protein, during fasting.

Finasteride's potential side effects, especially sexual dysfunction, are discussed, with emphasis on hormonal balance between testosterone and estradiol. Users share experiences with finasteride, minoxidil, and dutasteride, highlighting the variability in side effects and the influence of mindset and lifestyle.

Finasteride may decrease free testosterone by increasing SHBG, potentially causing side effects like reduced libido and hormonal changes. Some find it effective for hair loss, while others experience negative effects.

Finasteride has no effect on the user's estradiol levels, and body fat may influence aromatization. The user is on testosterone replacement therapy and uses everyday injections to manage high RBC count, with plans to measure DHT, DHEA-S, and pregnenolone levels.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Dutasteride and finasteride may temporarily affect semen quality but are unlikely to cause permanent infertility. The Kim et al. study is criticized for poor methodology, and many prefer hair retention over potential fertility concerns, using treatments like dutasteride, finasteride, and minoxidil.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

A user discovered they have naturally low DHT levels and is concerned about taking finasteride, which could further lower these levels. They are seeking advice on whether to proceed with the treatment given their hormone levels are within the normal range.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.

Aminexil is similar to Minoxidil but less effective and not widely used, with some users reporting minor regrowth. It is not FDA-approved and has been removed from some products, though some people still use it, often in combination with Minoxidil.

The user got blood work to check hormone levels before starting Finasteride for hair loss and is seeking advice on interpreting the results. They are considering hormone levels in relation to potential side effects of Finasteride.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.